BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26763733)

  • 1. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
    Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ
    Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
    Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
    J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
    Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
    Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages.
    Hattori Y; Yamashita J; Sakaida C; Kawano K; Yonemochi E
    J Liposome Res; 2015; 25(2):131-40. PubMed ID: 25203609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth.
    Salzano G; Zappavigna S; Luce A; D'Onofrio N; Balestrieri ML; Grimaldi A; Lusa S; Ingrosso D; Artuso S; Porru M; Leonetti C; Caraglia M; De Rosa G
    J Biomed Nanotechnol; 2016 Apr; 12(4):811-30. PubMed ID: 27301207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
    Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
    Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbon Dots Embedded Magnetic Nanoparticles @Chitosan @Metal Organic Framework as a Nanoprobe for pH Sensitive Targeted Anticancer Drug Delivery.
    Chowdhuri AR; Singh T; Ghosh SK; Sahu SK
    ACS Appl Mater Interfaces; 2016 Jul; 8(26):16573-83. PubMed ID: 27305490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-Inclusive Inorganic-Organic Hybrid Systems for the Controlled Release of the Osteoporosis Drug Zoledronate.
    Vassaki M; Lazarou S; Turhanen P; Choquesillo-Lazarte D; Demadis KD
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
    Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
    Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.
    Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Ogorka J; Kumar S; Zhang JA; Gabizon A
    J Control Release; 2010 Aug; 146(1):76-83. PubMed ID: 20462513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.
    Marra M; Salzano G; Leonetti C; Tassone P; Scarsella M; Zappavigna S; Calimeri T; Franco R; Liguori G; Cigliana G; Ascani R; La Rotonda MI; Abbruzzese A; Tagliaferri P; Caraglia M; De Rosa G
    Nanomedicine; 2011 Dec; 7(6):955-64. PubMed ID: 21453789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid - a multiplicity of anti-cancer action.
    Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
    Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic Acid Functionalized Zirconium-Based Metal-Organic Frameworks as Drug Carriers for Active Tumor-Targeted Drug Delivery.
    Dong H; Yang GX; Zhang X; Meng XB; Sheng JL; Sun XJ; Feng YJ; Zhang FM
    Chemistry; 2018 Nov; 24(64):17148-17154. PubMed ID: 30125400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic nanoscale metal organic frameworks for potential targeted anticancer drug delivery, imaging and as an MRI contrast agent.
    Ray Chowdhuri A; Bhattacharya D; Sahu SK
    Dalton Trans; 2016 Feb; 45(7):2963-73. PubMed ID: 26754449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method.
    Li X; Naguib YW; Cui Z
    Int J Pharm; 2017 Jun; 526(1-2):69-76. PubMed ID: 28455136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoscale metal-organic frameworks for biomedical imaging and drug delivery.
    Della Rocca J; Liu D; Lin W
    Acc Chem Res; 2011 Oct; 44(10):957-68. PubMed ID: 21648429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.
    Ramanlal Chaudhari K; Kumar A; Megraj Khandelwal VK; Ukawala M; Manjappa AS; Mishra AK; Monkkonen J; Ramachandra Murthy RS
    J Control Release; 2012 Mar; 158(3):470-8. PubMed ID: 22146683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic Acid-containing Nanoparticles With Minimum Premature Release Show Enhanced Activity Against Extraskeletal Tumor.
    Li X; Valdes SA; Alzhrani RF; Hufnagel S; Hursting SD; Cui Z
    ACS Appl Mater Interfaces; 2019 Feb; 11(7):7311-7319. PubMed ID: 30689348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.